Biogen (BIIB) PT Raised to $390 at Bernstein
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $222.15 -0.33%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 92
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 92
Join SI Premium – FREE
Bernstein analyst Aaron Gal raised the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $370.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA
- Stifel Financial (SF) PT Lowered to $84 at UBS
- LPL Financial Holdings (LPLA) PT Lowered to $390 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Sanford C. BernsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
